bispecific antibody


Also found in: Wikipedia.

bispecific antibody

1. an antibody having specificity for a target cell on one arm and for a treatment or killing agent on the other.
See also: bivalent antibody.
2. synthetic antibody constructed by cross-linking Fab fragments from separate monoclonal antibodies.

bispecific antibody

Immunology
An antibody or an antiserum raised against two antigens or proteins on the surface of different cells.

Molecular biology
A bioengineered antibody with 2 different binding sites that recognise 2 different antigens.
References in periodicals archive ?
Merus (MRUS) announced that Ono Pharmaceutical (OPHLY) has exercised its option under an agreement executed in April 2014 to enter into a new research and license agreement utilizing Merus' proprietary Biclonics technology platform to generate a bispecific antibody that binds to a combination of targets designed for the treatment of autoimmune diseases.
M2 PHARMA-March 5, 2018-Selexis SA Signs CLAs with Xencor to Develop Bispecific Antibody Drug Candidates
ATOR-1015 is a first-in-class bispecific antibody that targets CTLA-4 and OX40 and it was developed with the company's bispecific technology.
ATOR-1015 is a first-in-class bispecific antibody that targets CTLA-4 and OX40 and was created with the company's unique bispecific technology.
Safety and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody REGN2810 Alone or in Combination with REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-Lymphoid Malignancies
PMC-001(=DIG-KT), next generation bispecific antibody neutralizing both VEGF-KDR and Angiopoietin-TIE2 pathways is superior to bevacizumab and Tanibirumab in preliminary studies.
Also, BioNovion's pipeline includes an APRIL antagonist and five bispecific antibody programs against immune-oncology targets under collaboration with Genmab using Genmab's proprietary DuoBody Technology.
A balance of both academic and industry experts will facilitate discussion on novel antibody targets, antibody selection methods and strategies, bispecific antibody & fusion proteins, immunomodulatory biotherapy for cancer, and the next generation of protein engineering.
They wondered if there was a way to create a bispecific antibody not from fragments, but from 2 complete half-antibodies.
Created by the Company's proprietary DOCK-AND-LOCK method, the bispecific antibody is currently in a number of clinical trials for pretargeted immunoPET imaging and radioimmunotherapy of patients with CEA-expressing cancers.
They also created a second bispecific antibody aimed at additional targets.
As a result, when a bispecific antibody complex binds to healthy tissue away from light, it cannot activate T-cells.